Harvard Business Review

SEPTEMBER 12, 2012

The study assembles considerable evidence about the hidden business model of major pharmaceutical companies: to devote most of their research budget to developing hundreds of drugs that provide few if any advantages over existing drugs and then market them heavily to doctors and patients. See The Risks of Prescription Drugs (Columbia 2010).

Business Model 15

Business Model Company Pharmaceuticals Price 15

Harvard Business Review

MAY 1, 2015

The details of the proposed new rules are sure to raise questions about things like fee disclosures and conflicts of interest. The reality, however, is that this issue is deeply connected to how we make decisions on digital displays, which is of crucial importance to investors, businesses, and policy makers.

Planning 8

Planning Short-term Long-term Policies 8

Harvard Business Review

DECEMBER 6, 2012

For example, the SEC in 2010 had charged Goldman with misleading some of the parties to a billion dollar transaction (involving a complex derivative called a synthetic collateralized debt obligation), alleging specific facts about undisclosed conflicts of interest. Goldman settled within months for $550 million.

Conflict of Interest 8

Conflict of Interest CEO Asset Management Committee 8

Harvard Business Review

FEBRUARY 3, 2017

By that I mean that pharma companies should develop innovative treatments for pervasive unmet medical needs; avoid corruption, collusion, and other unethical marketing practices; and make sure that their products reach as many patients around the world as possible. Mitigate the risk of unethical conduct. Enhance corporate reputations.

Reputation 8

Reputation Pharmaceuticals Price Business Model 8

Harvard Business Review

MARCH 2, 2017

On February 3 President Trump issued an executive order directing the Treasury Department to conduct a sweeping review of financial regulation, including Dodd-Frank , the financial reform bill passed, in 2010, as part of the Obama administration’s response to the 2008 financial crisis and subsequent recession.

Banking 8

Banking Crisis System Compliance 8